Certara to Present at the BofA Securities 2021 Virtual Health Care Conference

April 30, 2021 | Last Trade: US$13.07 0.53 -3.90

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will be participating in the BofA Securities 2021 Virtual Health Care Conference.

William Feehery, CEO, and Andrew Schemick, CFO, are scheduled to present on Tuesday, May 11, 2021 at 2:45 p.m. ET. A live webcast will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Stock Quote

Last Trade:	US$13.07
Daily Change:	-0.53 -3.90
Daily Volume:	2,094,695
Market Cap:	US$2.100B

September 04, 2025 Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster August 06, 2025 Certara Reports Second Quarter 2025 Financial Results August 04, 2025 Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling July 31, 2025 Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform July 08, 2025 Certara Announces Expansion of Clinical Technology Collaboration with Merck LOAD MORE NEWS

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE